Peptigrade

Metabolic & Weight

Semaglutide

GLP-1 receptor agonist·Also known as: Ozempic, Wegovy, Rybelsus

FDARegulatory status

Approved (2017 diabetes, 2021 obesity)

WADARegulatory status

Permitted in athletic competition

Regulatory note ·Available as Ozempic (T2D injectable), Wegovy (obesity injectable), and Rybelsus (oral). Marketed by Novo Nordisk. One of the most-studied peptide drugs of the past decade.

§ The quick take

TL;DR · Editor’s summary

Semaglutide is the most evidence-supported peptide drug on this site. For type 2 diabetes and obesity, the data is overwhelming — multiple Phase 3 trials, 8+ years of post-marketing surveillance for Ozempic in diabetes (FDA approval December 2017) with shorter post-marketing duration for Wegovy in obesity (approval June 2021), and FDA approvals across three formulations.

The known side effect profile is well-characterized (GI effects in 40–80% of users, gallbladder events, rare pancreatitis). The questions that remain are about long-tail use cases — kidney disease, MASH, addiction, neurodegeneration — where the evidence is rapidly accumulating but not yet at A-grade.

§ Grade matrix

The grade
per outcome.

One peptide can earn very different grades for different uses. Here is every outcome we’ve graded for Semaglutide, sorted by strength of evidence.

A

Type 2 diabetes

Strong

SUSTAIN program (10 RCTs, ~10,000 patients) showed consistent HbA1c reduction of 1.2–1.8% with cardiovascular benefit.

178 studiesUpdated Apr 02, 2026
A

Obesity (BMI ≥30)

Strong

STEP program showed 14.9% mean body weight reduction at 68 weeks vs 2.4% on placebo. Largest non-surgical effect on record at the time.

64 studiesUpdated Apr 02, 2026
A

Cardiovascular risk reduction

Strong

SUSTAIN-6 and SELECT showed reduced MACE in T2D and overweight/obese patients with established CVD.

41 studiesUpdated Mar 18, 2026
B

Chronic kidney disease (T2D)

Promising

FLOW trial (n=3,533) showed 24% reduction in major kidney events. Approved label expansion likely.

22 studiesUpdated Feb 14, 2026
B

MASH / NASH

Promising

ESSENCE Phase 3 showed histological resolution of MASH in 36.8% of treated vs 22.4% on placebo at 72 weeks.

18 studiesUpdated Mar 28, 2026
C

Alcohol use disorder

Mixed

Early signal from observational and small interventional studies. RCTs underway. Mechanism plausible via reward pathway modulation.

9 studiesUpdated Jan 30, 2026

§ Why this grade

Sub-scores for this outcome.

Type 2 diabetes

Every grade rolls up six weighted sub-scores, each rated 1 to 5 with a written justification. Here is how the top-outcome grade was constructed.

Mechanism understood

5 / 5

GLP-1 receptor pharmacology fully characterized. Multiple confirmatory mechanism studies.

Human studies (count + quality)

5 / 5

10 Phase 3 RCTs in SUSTAIN program, 10,000+ patients, plus extensive real-world data.

Effect vs placebo

5 / 5

Consistent 1.2–1.8% HbA1c reduction vs placebo across trials.

Long-term safety data

4 / 5

8+ years post-marketing data. Known: GI effects, gallbladder, rare pancreatitis. Thyroid signal in rodents.

Side effect profile

3 / 5

Well-characterized but real — 40–80% experience GI effects, ~10% discontinue.

Regulatory status

5 / 5

FDA-approved. EMA-approved. Standard of care for T2D.

§ What the science says

How Semaglutide
works.

The scientific explanation of the molecule and its proposed mechanism, with a plain-English translation — written at an 8th-grade reading level — in the teal callouts below each section. Every claim is linked to a primary source below.

What it is

Semaglutide is a synthetic 31-amino-acid peptide that mimics the body's natural glucagon-like peptide-1 (GLP-1). It was developed by Novo Nordisk as a long-acting GLP-1 receptor agonist and approved by the FDA for type 2 diabetes in 2017 (Ozempic), oral diabetes in 2019 (Rybelsus), and chronic weight management in 2021 (Wegovy). It has become one of the most-prescribed and most-studied drugs in the world.

In plain English

Semaglutide is a 31-amino-acid drug molecule that works by mimicking a natural gut hormone called GLP-1 (glucagon-like peptide-1). Your intestines release GLP-1 after you eat — it tells your pancreas to release insulin, tells your brain you're full, and slows down how fast food leaves your stomach. Semaglutide does all of this, but lasts much longer than the natural hormone (which breaks down in minutes). One injection a week is enough. It was developed by the Danish pharmaceutical company Novo Nordisk and has received FDA approvals under three brand names: Ozempic (weekly injection for type 2 diabetes), Rybelsus (daily pill for type 2 diabetes), and Wegovy (weekly injection for obesity). It is not a peptide supplement in the wellness sense — it is a fully approved pharmaceutical drug with large clinical trials behind it.

How it works

  1. 01

    Semaglutide binds and activates the GLP-1 receptor, mimicking the action of the native incretin hormone GLP-1 that the gut releases after meals.

  2. 02

    It stimulates glucose-dependent insulin secretion from pancreatic beta cells — meaning it only triggers insulin release when blood sugar is elevated, which is why hypoglycemia risk is low compared to insulin.

  3. 03

    It suppresses glucagon secretion from alpha cells, reducing hepatic glucose output.

  4. 04

    It slows gastric emptying, prolonging satiety after meals. This is the primary mechanism for weight loss.

  5. 05

    Central GLP-1 receptors in the hypothalamus reduce appetite and food reward signaling — a key reason it produces weight loss beyond what gastric slowing alone would predict.

§ Investigated uses

What it’s
been studied for.

Investigated does not mean proven. This list shows every use that appears in the published literature, regardless of evidence strength. See the grade matrix above for which ones have actually held up.

  • Type 2 diabetes mellitus

    FDA-approved (Ozempic, Rybelsus) — Grade A

  • Chronic weight management (obesity)

    FDA-approved (Wegovy) — Grade A

  • Cardiovascular event reduction

    FDA label expansion, SELECT trial — Grade A

  • Diabetic chronic kidney disease

    Phase 3 FLOW positive — Grade B

  • MASH (metabolic dysfunction-associated steatohepatitis)

    Phase 3 ESSENCE positive — Grade B

  • Alcohol and substance use disorders

    Early-phase trials underway

  • Alzheimer's disease (oral semaglutide, evoke trials)

    Phase 3 reading out 2026

§ The honest gaps

What we don’t
know yet.

Every peptide page on this site is required to include this section. Absence of evidence is information. If we don’t flag the gaps, we’re lying by omission.

  • !

    Long-term effects of weight loss maintenance on lean mass, bone density, and metabolic adaptation are still being characterized.

  • !

    Whether the cardiovascular and kidney benefits are mediated by weight loss alone, glycemic control, or direct receptor effects in those tissues remains debated.

  • !

    Optimal duration of therapy for weight loss — is it lifelong, or can patients taper? STEP-4 showed weight regain on discontinuation, but tapering protocols are not well-studied.

  • !

    Real-world effect size in non-trial populations appears smaller than RCT data — selection bias and adherence patterns matter.

  • !

    Risk of GLP-1-associated medullary thyroid carcinoma in humans is theoretical (rodent data only) but the FDA contraindication remains.

§ On YouTube

What experts and
influencers say.

We index YouTube content discussing Semaglutideand tag every speaker by credential and trust level. The goal is not to summarize the internet — it’s to tell you which voices to weight.

  • Semaglutide: Mechanism, Evidence, and Long-Term Outlook

    Peter Attia MD·MD, Longevity / Internal Medicine

    Detailed walk-through of SUSTAIN and STEP trial data with measured discussion of risks.

    Verified credentials

  • GLP-1 Drugs Explained

    Eric Topol·MD, Cardiology / Director Scripps Research

    Clinical-grade summary of cardiovascular evidence and emerging indications.

    Verified credentials

§ Citations

Every claim,
linked to source.

All 5 sources informing this page, with DOI or PubMed identifiers. Click through to the primary literature.

  1. [01]

    Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6)

    Marso SP, Bain SC, Consoli A, et al. · N Engl J Med · 2016

    RCTPMID 27295427
  2. [02]

    Once-weekly semaglutide in adults with overweight or obesity (STEP-1)

    Wilding JPH, Batterham RL, Calanna S, et al. · N Engl J Med · 2021

    RCTPMID 33567185
  3. [03]

    Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · N Engl J Med · 2023

    RCTPMID 37952131
  4. [04]

    Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW)

    Perkovic V, Tuttle KR, Rossing P, et al. · N Engl J Med · 2024

    RCTPMID 38869091
  5. [05]

    Semaglutide in patients with metabolic dysfunction-associated steatohepatitis (ESSENCE)

    Newsome PN, Sanyal AJ, Engebretsen KA, et al. · N Engl J Med · 2024

    RCTPMID 39282899

§ Adjacent peptides

Worth reading
alongside this.

Compare

Tirzepatide

The dual GIP/GLP-1 successor with stronger weight loss effect. Same mechanism family.

Read its grades

Compare

Retatrutide

Triple agonist (GIP/GLP-1/glucagon) showing even larger Phase 2 weight loss effects.

Read its grades

Where to research further

Looking for Semaglutide
for laboratory research?

Peptigrade does not sell peptides. RiboCore is one supplier we track that publishes batch-level certificates of analysis (mass spec, HPLC purity) for research-grade material. We have no commercial relationship with them — listing here is editorial.

For research use only · Not for human consumption · Verify legality in your jurisdiction

View at RiboCoreHow we evaluate suppliers →